• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term assessment of no evidence of disease activity in relapsing-remitting MS.

作者信息

De Stefano Nicola, Stromillo Maria Laura, Giorgio Antonio, Battaglini Marco, Bartolozzi Maria Letizia, Amato Maria Pia, Sormani Maria Pia

机构信息

From the University of Siena (N.D., M.L.S., A.G., M.B.); the Hospital of Empoli (M.L.B.); the University of Florence (M.P.A.); and the University of Genoa (M.P.S.), Italy.

出版信息

Neurology. 2015 Nov 10;85(19):1722-3. doi: 10.1212/WNL.0000000000002105. Epub 2015 Oct 14.

DOI:10.1212/WNL.0000000000002105
PMID:26468405
Abstract
摘要

相似文献

1
Long-term assessment of no evidence of disease activity in relapsing-remitting MS.复发缓解型多发性硬化症无疾病活动证据的长期评估
Neurology. 2015 Nov 10;85(19):1722-3. doi: 10.1212/WNL.0000000000002105. Epub 2015 Oct 14.
2
Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.挪威西部霍达兰郡良性多发性硬化症的长期随访
Mult Scler. 2009 Aug;15(8):942-50. doi: 10.1177/1352458509106511. Epub 2009 Jul 1.
3
Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.长期口服避孕药的使用对复发性缓解型多发性硬化临床病程的影响。
Fertil Steril. 2014 Jul;102(1):116-22. doi: 10.1016/j.fertnstert.2014.03.054. Epub 2014 Apr 29.
4
Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.多发性硬化症的十年预后：复发缓解型患者预后较好，但原发进展型患者并非如此。
Eur J Neurol. 2015 Mar;22(3):507-e35. doi: 10.1111/ene.12600. Epub 2014 Dec 16.
5
Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.预测复发缓解型多发性硬化症的严重程度：横断面和短期随访 MRI 数据的贡献。
Mult Scler. 2011 Jun;17(6):695-701. doi: 10.1177/1352458510394454. Epub 2011 Jan 12.
6
Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.健康相关生活质量作为复发缓解型多发性硬化患者长期残疾的独立预测因子。
Eur J Neurol. 2013 Jun;20(6):907-14, e78-9. doi: 10.1111/ene.12087. Epub 2013 Jan 24.
7
Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.评估 7 年纵向多发性硬化症队列中的无疾病活动证据。
JAMA Neurol. 2015 Feb;72(2):152-8. doi: 10.1001/jamaneurol.2014.3537.
8
ADC measurements in various patterns of multiple sclerosis lesions.多发性硬化症病变不同模式下的表观扩散系数测量
J Med Assoc Thai. 2006 Feb;89(2):196-204.
9
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史：一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
10
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.向继发进展型多发性硬化转变过程中的诊断不确定性
Mult Scler. 2014 Oct;20(12):1654-7. doi: 10.1177/1352458514521517. Epub 2014 Feb 3.

引用本文的文献

1
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.在临床实践中接受阿仑单抗治疗的多发性硬化症患者生活质量的改善：LEMVIDA研究。
J Patient Rep Outcomes. 2024 Dec 18;8(1):148. doi: 10.1186/s41687-024-00822-9.
2
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.在复发型多发性硬化症的ULTIMATE 3期研究中，与特立氟胺相比，乌布利昔单抗治疗无疾病活动证据的改善情况。
Front Neurol. 2024 Oct 24;15:1473284. doi: 10.3389/fneur.2024.1473284. eCollection 2024.
3
Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
芬戈莫德对复发缓解型多发性硬化症患者局灶性和弥漫性损伤的影响 - “EVOLUTION”研究。
J Neurol. 2024 Sep;271(9):6181-6196. doi: 10.1007/s00415-024-12590-z. Epub 2024 Jul 29.
4
Multiple sclerosis clinical decision support system based on projection to reference datasets.基于参考数据集投影的多发性硬化症临床决策支持系统。
Ann Clin Transl Neurol. 2022 Dec;9(12):1863-1873. doi: 10.1002/acn3.51649. Epub 2022 Nov 22.
5
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.在 TOPAZ 扩展研究中，对 CARE-MS I 和 II 患者进行事后分析，结果显示：在疾病高度活跃患者中经过 9 年随访的阿仑单抗的疗效和安全性。
CNS Drugs. 2020 Sep;34(9):973-988. doi: 10.1007/s40263-020-00749-x.
6
Multiple sclerosis.多发性硬化症。
Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4.
7
Population-based study of "no evident disease activity" in MS.基于人群的多发性硬化症“无明显疾病活动”研究。
Neurol Neuroimmunol Neuroinflamm. 2018 Aug 16;5(6):e495. doi: 10.1212/NXI.0000000000000495. eCollection 2018 Nov.
8
Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.日本多发性硬化症患者在没有疾病活动证据的情况下存在脑容量损失。
Neurol Sci. 2018 Oct;39(10):1713-1716. doi: 10.1007/s10072-018-3487-y. Epub 2018 Jul 4.
9
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.用奥瑞珠单抗与干扰素β-1a治疗复发型多发性硬化症患者时按时间段进行的无疾病活动证据（NEDA）分析。
Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.
10
Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.脊髓作为脑磁共振成像的辅助手段在明确多发性硬化症“无疾病活动证据”中的应用
Int J MS Care. 2017 May-Jun;19(3):158-164. doi: 10.7224/1537-2073.2016-068.